🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/04/2012 | 36,14 | 36,37 | 35,26 | 35,49 | -1,88% | 3,07% | 1.977.500 |
| 13/04/2012 | 37,64 | 37,64 | 36,15 | 36,17 | -4,08% | 3,96% | 2.012.200 |
| 12/04/2012 | 36,94 | 38,00 | 36,91 | 37,71 | +1,84% | 2,95% | 2.008.200 |
| 11/04/2012 | 36,86 | 37,49 | 36,56 | 37,03 | +1,29% | 2,52% | 2.845.100 |
| 10/04/2012 | 38,00 | 38,07 | 36,51 | 36,56 | -4,07% | 4,11% | 3.296.600 |
| 09/04/2012 | 39,58 | 39,58 | 37,86 | 38,11 | -4,84% | 4,35% | 2.718.500 |
| 05/04/2012 | 40,37 | 40,67 | 39,62 | 40,05 | -1,28% | 2,60% | 2.105.700 |
| 04/04/2012 | 41,60 | 41,92 | 40,43 | 40,57 | -2,94% | 3,58% | 2.832.300 |
| 03/04/2012 | 40,43 | 41,85 | 40,21 | 41,80 | +3,26% | 4,06% | 2.414.000 |
| 02/04/2012 | 40,74 | 40,90 | 39,83 | 40,48 | -1,29% | 2,63% | 1.758.700 |
| 30/03/2012 | 40,88 | 41,35 | 40,51 | 41,01 | +1,16% | 2,05% | 1.591.100 |
| 29/03/2012 | 40,21 | 40,82 | 39,79 | 40,54 | +0,25% | 2,56% | 1.315.400 |
| 28/03/2012 | 41,08 | 42,00 | 40,27 | 40,44 | -1,25% | 4,21% | 1.475.600 |
| 27/03/2012 | 40,69 | 41,43 | 40,69 | 40,95 | +0,05% | 1,82% | 1.052.700 |
| 26/03/2012 | 41,36 | 41,56 | 40,37 | 40,93 | -0,99% | 2,88% | 1.834.100 |
| 23/03/2012 | 40,75 | 41,50 | 40,38 | 41,34 | +1,72% | 2,75% | 1.003.500 |
| 22/03/2012 | 41,08 | 41,46 | 40,17 | 40,64 | -1,10% | 3,14% | 1.616.300 |
| 21/03/2012 | 40,97 | 41,72 | 40,65 | 41,09 | +0,42% | 2,61% | 2.441.200 |
| 20/03/2012 | 41,53 | 41,70 | 40,83 | 40,92 | -1,73% | 2,09% | 1.712.500 |
| 19/03/2012 | 41,72 | 43,04 | 41,50 | 41,64 | -3,03% | 3,69% | 3.730.100 |
| 16/03/2012 | 42,62 | 43,07 | 41,96 | 42,94 | +0,30% | 2,60% | 3.735.200 |
| 15/03/2012 | 41,40 | 43,13 | 41,27 | 42,81 | +3,61% | 4,49% | 2.760.700 |
| 14/03/2012 | 41,86 | 42,20 | 41,26 | 41,32 | -0,96% | 2,25% | 1.739.900 |
| 13/03/2012 | 41,86 | 41,99 | 41,13 | 41,72 | +0,24% | 2,05% | 2.352.000 |
| 12/03/2012 | 41,81 | 42,19 | 41,51 | 41,62 | -0,41% | 1,63% | 1.197.200 |
| 09/03/2012 | 41,65 | 42,20 | 41,38 | 41,79 | +0,31% | 1,97% | 1.793.000 |
| 08/03/2012 | 40,79 | 41,93 | 40,58 | 41,66 | +2,28% | 3,31% | 2.087.000 |
| 07/03/2012 | 39,75 | 40,89 | 39,70 | 40,73 | +2,62% | 2,99% | 2.300.600 |
| 06/03/2012 | 40,10 | 40,22 | 38,90 | 39,69 | -1,76% | 3,29% | 2.210.100 |
| 05/03/2012 | 40,50 | 40,81 | 40,15 | 40,40 | -0,81% | 1,63% | 2.665.800 |